WuXi Biologics/药明生物

Thank you to all who joined us at San Francisco CRDMO Day on May 20th! It was an inspiring day of insightful discussions and meaningful networking with industry leaders shaping the future of biologics development and manufacturing. The event featured discussions on the latest advances in biologics development and manufacturing — from bispecifics and ADCs to bioprocess development, tech transfer, formulation, and drug product delivery. Together, we’re advancing quality, flexibility, and speed. #WuXiBiologics #CRDMODay #BiologicsDevelopment #Biomanufacturing #Innovation

Attending CPHI Americas in Philadelphia, PA (June 2–4)? Connect with Jason He, Head of WuXi Vaccines Business Development and CMC Management, to discuss your biologics outsourcing needs—from early R&D through commercial GMP manufacturing. Learn how WuXi Biologics can support your program with integrated development and manufacturing solutions designed to accelerate your path to clinic and commercialization. Schedule a meeting to discuss your project needs: https://lnkd.in/gvNFGynY

Advanced technologies. Proven execution. Reliable timelines. Our US drug product site combines state-of-the-art filling capabilities with rapid technology transfer and onsite clinical supply—all supported by an experienced team of subject matter experts. See how we accelerate your drug product development and manufacturing. 🎥 Watch the video today.

Meet PatroLab, a digital platform that advances biologics manufacturing from reactive troubleshooting to predictive, prescriptive control. The platform uniquely synthesizes real-time monitoring, modeling, and automation to transform bioprocess data into early insights for adjustments before product quality impacts. With integrated PAT, digital twin simulation, and model predicative control, PatroLab empowers manufacturers to: • Detect process drift earlier • Accelerate and simplify deviation investigations • Improve process efficiency and consistency • Strengthen PPQ and CPV outcomes • Enable real-time release testing for faster drug substance release The result: greater visibility, smarter control, and faster, more reliable manufacturing. Learn more: https://lnkd.in/erPhsJVq #BiologicsManufacturing #ProcessAnalytics #DigitalTwin #PredictiveControl #Bioprocessing #ProcessOptimization #ManufacturingInnovation

Get ready to connect us on the Innovation-Powered Biosafety Testing Seminar? June 4 & 5th, Join Us in Korea! We are excited to invite you in Seoul and Osong focused on Innovation-Powered Biosafety Testing for biopharmaceuticals. • Seoul｜June 4th, 2026 | 10:00–14:00 • Osong｜June 5th, 2026 | 10:00–14:00 🎯 Real world case studies and practical regulatory insights will be shared. Whether you're in CMC, quality control, regulatory affairs, or drug development, this session will provide actionable takeaways to help move your pipeline forward. • Advancing Viral Safety with Next-Generation Sequencing*: Regulatory Expectations, Validation, and Real-World Applications • Data Insights from a Decade of BLA Viral Clearance Studies: Ensuring Regulatory Submission Success • Built on Quality, Driven by Speed: Conventional and NGS/PCR Solution for UPB Release Testing • Fast & Accurate: GMP Compliant Genetic Stability Study by Long Read NGS Technology • One-stop Biosafety Solution for Viral Vector Products: Enable Regulatory Readiness • Evolving Frontiers in Viral Clearance: Industry Trends and Adaptive Solutions 👉 Register and Meet us in Seoul: https://lnkd.in/eN9_vn8D 👉 Register and Meet us in Osong: https://lnkd.in/eM6rhY5C (*Note: WuXi Biologics ' Next-Generation Sequencing testing technology is only for adventitious agent screening in test articles. It does not analyze or interpret human genomic data from cell lines.) #WuXiBiologics #BiosafetyTesting #NGS #Next-GenerationSequencing #ViralSafety #PCR #Viral Clearance #CRDMO #Biologics #Regulatory #CGT #Biopharmaceuticals #CellAndGeneTherapy #BiotechInnovation #Comercial #GeneticStability #BLA

Missed the live session? Watch it on demand. Register now for “WuXia™ TrueSite: Targeted Integration for Faster Cell Line Development and High, Stable Protein Expression.” Discover how WuXi Biologics’ WuXia TrueSite platform is advancing CHO cell line development through targeted integration—delivering high productivity, strong stability, and consistent protein expression. Learn how the platform supports antibody titers exceeding 6 g/L from stable pools and 8 g/L from clones while helping accelerate CMC timelines to 10 months or less. Key takeaways: • Advantages of targeted integration for CHO cell line development • How WuXia TrueSite enables high productivity and stability • Strategies to accelerate clinical advancement Watch on demand: https://lnkd.in/egQE3BWG #WuXiaTrueSite #CellLineDevelopment #TargetedIntegration #CHOCells #CMCAcceleration

Interphex Week kicks off today in Tokyo, Japan's largest pharmaceutical and biotechnology trade show. 🌟 We are exhibiting at Hall 3, Booth14-46. 🌟 Our team will be on-site throughout the week to connect with industry leaders and professionals from across the sector. We look forward to seeing you at the booth! 🎉 #CRDMO #biologics #biotechnology #Tokyo

Great to be in Tokyo this week for our third CRDMO Day, where we connected with senior leaders and experts across Japan's biopharma industry. Together, we explored how to accelerate biologics innovation from IND to commercialization—sharing insights, experiences, and best practices. Building on our strong capabilities and track record, we look forward to deepening partnerships with Japanese companies across R&D and manufacturing, especially in complex modalities where Japan is at the forefront globally. 👉 For more on the event, please visit: https://lnkd.in/gkWWjbNF #CRDMO #biologics #innovation #commercialization #complexmodality

May is Asian American and Pacific Islander Heritage (AAPI) Month. The Northeast CMC management team at WuXi Biologics and their families attended the AAPI 5K Run & Walk in Lexington, MA, on May 10th, joining over 600 runners and walkers. This year’s theme, “Better Together: From Lex250 to America250,” highlights the importance of unity and shared progress. We celebrate the significant contributions of the AAPI community to this country and the idea that we are stronger together. 

Using high-titer WuXian Transient™ platform, WuXi Biologics CRO Services successfully produced 400 mg Fab’ from 1 L transient CHO, with exceptional purity confirmed by both SEC-HPLC and Intact Mass analysis. Check out more case studies: https://lnkd.in/eEEcwS6W Follow WuXi Biologics CRO Services for the latest publications, case studies, expert-led webinars, and industry insights.